Lymphoma is the most common blood cancer in dogs. The standard of care for the most frequent type of lymphoma, multicentric B cell lymphoma, is a multi-agent chemotherapy protocol (CHOP). While this treatment can extend a patient's life expectancy, it is generally not curative. Most patients eventually relapse and die of the disease. Currently, there are no reliable markers to predict when a patient might relapse.
To assess whether a patient's tumor burden during and after therapy can predict time to relapse or overall survival.
A patient's tumor burden is assessed through next generation sequencing using a small blood sample.
The study will establish a new and potentially more sensitive method to monitor residual tumor burden. Residual tumor burden might be used to predict outcome. More sensitive methods of tumor detection might allow improvements of chemotherapy protocols in future trials.
This study is funded by Pet Trust.